Diagnocure, Inc. (DGCRF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Diagnocure, Inc. (DGCRF) stock?
Diagnocure, Inc. (DGCRF) no longer trades on public markets. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Diagnocure, Inc. (DGCRF). Diagnocure, Inc. is a Canadian life sciences company specializing in the development and commercialization of molecular diagnostic tests for cancer. Their focus is on early detection and management of prostate and colorectal cancers. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for DGCRF: DGCRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DGCRF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
DGCRF: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Diagnocure, Inc. (DGCRF) Healthcare & Pipeline Overview
Diagnocure, Inc., a Canadian life sciences company founded in 1994, focuses on developing and commercializing molecular diagnostic tests for cancer, particularly prostate and colorectal cancers, operating in the specialized medical diagnostics sector with a focus on the Canadian market.
What Is the Investment Thesis for DGCRF?
Diagnocure, Inc. presents a focused investment opportunity within the specialized field of molecular cancer diagnostics. The company's emphasis on prostate and colorectal cancer testing, particularly within the Canadian market, offers a niche position. A gross margin of 100.0% indicates strong pricing power on existing products, but the company's negative profit margin of -698.6% highlights significant operational challenges. Key catalysts include potential regulatory approvals for new diagnostic tests and expansion into new markets. However, the company's small size (3 employees) and negative beta of -15.95 suggest high volatility and sensitivity to market conditions. Success hinges on effective commercialization of existing products and successful development of new diagnostic solutions.
Based on FMP financials and quantitative analysis
DGCRF Key Highlights
Gross Margin of 100.0% indicates strong pricing power on existing products.
- Negative Profit Margin of -698.6% highlights significant operational challenges.
- Market Cap of $0.00B reflects the company's small size and potential risks.
- The company focuses on molecular diagnostic tests for the detection and management of cancer, specifically prostate and colorectal cancers.
- The company's headquarters are located in Quebec, Canada, focusing on the Canadian market.
Who Are DGCRF's Competitors?
DGCRF is benchmarked below against 4 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CTBO Cantabio Pharmaceuticals, Inc. | $1.01 | 0.00% | — | |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $0.82 | -0.87% | $35.7M | 435-pillar |
| SI SHOULDER INNOVATIONS, INC. | $19.27 | +0.84% | $400M | 365-pillar |
| EBOSY EBOS Group Limited | $26.00 | -0.38% | $1.33B | 429-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are DGCRF's Key Strengths?
Proprietary molecular diagnostic tests for cancer.
- High gross margin (100.0%) indicates strong pricing power.
- Focus on specific cancer types (prostate and colorectal).
- Established presence in the Canadian market.
What Are DGCRF's Weaknesses?
Negative profit margin (-698.6%) indicates financial instability.
- Small company size (3 employees) limits resources.
- Reliance on a limited number of diagnostic tests.
- Limited geographic reach (primarily Canada).
What Could Drive DGCRF Stock Higher?
Potential regulatory approvals for new diagnostic tests in Canada.
- Expansion of marketing and sales efforts for existing diagnostic tests.
- Strategic partnerships with healthcare providers and research institutions.
- Publication of clinical trial results supporting the efficacy of diagnostic tests.
- Reimbursement coverage negotiations with public and private payers.
What Are the Key Risks for DGCRF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger diagnostic companies with greater resources.
- Regulatory changes affecting diagnostic testing and reimbursement.
- Technological advancements rendering existing tests obsolete.
- Dependence on a limited number of diagnostic tests.
- Financial instability due to negative profit margin.
What Are the Growth Opportunities for DGCRF?
- Expansion of PCA3 test market share: The PCA3 test for prostate cancer diagnosis represents a significant growth opportunity for Diagnocure. By increasing market penetration and adoption of the PCA3 test among urologists and primary care physicians in Canada, Diagnocure can drive revenue growth. The market for prostate cancer diagnostics is projected to grow as the aging population increases the incidence of the disease. Effective marketing and distribution strategies will be crucial for capturing a larger share of this market.
- Commercialization of Previstage GCC colorectal cancer staging test: The Previstage GCC colorectal cancer staging test offers another avenue for growth. By successfully commercializing this test and gaining acceptance among oncologists and surgeons, Diagnocure can tap into the growing market for colorectal cancer diagnostics. The test's ability to provide valuable information for treatment planning and prognosis makes it a noteworthy option for healthcare providers. Securing reimbursement coverage from public and private payers will be essential for driving adoption.
- Development of new molecular diagnostic tests: Investing in the development of new molecular diagnostic tests for other types of cancer represents a long-term growth opportunity. By expanding its product portfolio beyond prostate and colorectal cancer, Diagnocure can diversify its revenue streams and reduce its reliance on a limited number of tests. This requires ongoing research and development efforts, as well as strategic partnerships with research institutions and other biotech companies. Successful development and commercialization of new tests could significantly enhance Diagnocure's market position.
- Strategic partnerships and collaborations: Forming strategic partnerships and collaborations with other companies in the healthcare industry can accelerate Diagnocure's growth. Collaborating with pharmaceutical companies, diagnostic equipment manufacturers, or healthcare providers can provide access to new markets, technologies, and resources. These partnerships can also help Diagnocure expand its product offerings and improve its distribution channels. Identifying and securing mutually beneficial partnerships will be crucial for driving growth and innovation.
- Expansion into international markets: While currently focused on the Canadian market, Diagnocure could explore opportunities to expand its operations into international markets. This could involve licensing its diagnostic tests to companies in other countries or establishing a direct presence in key markets. International expansion would require careful consideration of regulatory requirements, market dynamics, and competitive landscape. However, it could significantly increase Diagnocure's revenue potential and market reach.
What Are DGCRF's Competitive Advantages?
- Proprietary molecular diagnostic tests.
- Patents protecting key diagnostic technologies.
- Established relationships with Canadian healthcare providers.
- Expertise in cancer diagnostics and molecular biology.
What Does DGCRF Do?
Diagnocure, Inc., established in 1994 and based in Quebec, Canada, is a life sciences company dedicated to the development and commercialization of innovative molecular diagnostic tests for cancer. The company's primary focus is on the early detection and management of prostate and colorectal cancers. Diagnocure offers a range of diagnostic tests, including the PCA3 test for prostate cancer diagnosis, the Guanylyl Cyclase C (GCC) marker, and the Previstage GCC colorectal cancer staging test for colorectal cancer patients. Additionally, they provide the PCP multi-marker prostate cancer test. Beyond cancer-specific diagnostics, Diagnocure provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company aims to improve cancer patient outcomes through advanced diagnostic solutions. Formerly known as DiagnoCure Inc. 9342-8530 Québec Inc., the company continues to operate from its headquarters in Quebec, focusing on the Canadian market.
What Products and Services Does DGCRF Offer?
- Develops molecular diagnostic tests for cancer.
- Commercializes diagnostic products in Canada.
- Offers PCA3 test for prostate cancer diagnosis.
- Provides Guanylyl Cyclase C (GCC) marker for colorectal cancer.
- Offers Previstage GCC colorectal cancer staging test.
- Provides PCP multi-marker prostate cancer test.
- Offers gene expression and copy number variation analysis.
- Provides mutation detection and SNP genotyping services.
How Does DGCRF Make Money?
- Develops and patents molecular diagnostic tests.
- Commercializes tests through direct sales and distribution in Canada.
- Generates revenue from sales of diagnostic tests to hospitals, clinics, and laboratories.
- Provides laboratory services related to gene expression and mutation analysis.
What Industry Does DGCRF Operate In?
Diagnocure, Inc. operates within the medical specialties industry, a segment of the broader healthcare sector focused on specialized diagnostic and treatment solutions. The industry is characterized by rapid technological advancements, increasing demand for personalized medicine, and stringent regulatory requirements. Competition includes established diagnostic companies and emerging biotech firms. Diagnocure's focus on molecular diagnostics for prostate and colorectal cancer positions it within a growing niche, driven by the increasing prevalence of these cancers and the demand for early and accurate detection methods. The Canadian market offers specific opportunities and challenges related to healthcare regulations and reimbursement policies.
Who Are DGCRF's Key Customers?
- Hospitals and clinics in Canada.
- Laboratories performing cancer diagnostics.
- Oncologists and urologists.
- Research institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 50 |
| 2026-08-24 | 50 |
| 2026-08-25 | 50 |
| 2026-08-26 | 50 |
What changed?
The score has stayed at 50.
Over the same 3 days the stock moved +0.0%.
Company Profile
Diagnocure, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Quebec, CA. The company is led by CEO Yves Fradet F.R.C.S.,. DGCRF has traded publicly since 2009.
Financial Health
Diagnocure, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
DGCRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary molecular diagnostic tests for cancer.
- High gross margin (100.0%) indicates strong pricing power.
- Focus on specific cancer types (prostate and colorectal).
- Established presence in the Canadian market.
Bear Case
- Negative profit margin (-698.6%) indicates financial instability.
- Small company size (3 employees) limits resources.
- Reliance on a limited number of diagnostic tests.
- Limited geographic reach (primarily Canada).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DGCRF Latest News
No recent news available for DGCRF.
Leadership: Yves Fradet F.R.C.S.,
CEO
Yves Fradet is a medical professional with the designation F.R.C.S., indicating a Fellowship of the Royal College of Surgeons. His background likely includes extensive experience in the medical field, potentially specializing in surgery or a related discipline. Given his role as CEO of Diagnocure, he likely possesses a combination of medical expertise and business acumen. His leadership is pivotal in guiding the company's strategic direction and overseeing the development and commercialization of its cancer diagnostic products.
Track Record: As CEO of Diagnocure, Yves Fradet is responsible for overseeing the company's operations and strategic initiatives. His track record would include achievements related to the development and commercialization of the company's diagnostic tests, such as the PCA3 test and the Previstage GCC colorectal cancer staging test. His leadership is crucial for navigating the regulatory landscape and securing reimbursement coverage for the company's products. Given the company's small size, his leadership is critical for driving growth and innovation.
DGCRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Diagnocure, Inc. may not meet the minimum financial or reporting standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in DGCRF.
- Thin trading volume can lead to significant price volatility.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- Lack of regulatory oversight compared to major exchanges.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's cash flow and financial stability.
- Understand the company's capital structure and potential dilution.
- Monitor news and announcements related to the company.
- The company has been in operation since 1994.
- Focus on developing and commercializing cancer diagnostic tests.
- CEO with medical background (Yves Fradet F.R.C.S.).
- Presence in the Canadian market.
- Development of proprietary diagnostic tests (PCA3, Previstage GCC).
DGCRF Healthcare Stock FAQ
What happened to Diagnocure, Inc. (DGCRF) stock?
Diagnocure, Inc. (DGCRF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy DGCRF shares?
No. DGCRF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for DGCRF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before DGCRF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Diagnocure, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Diagnocure, Inc. do?
Diagnocure, Inc. is a life sciences company specializing in the development and commercialization of molecular diagnostic tests for cancer, primarily focusing on prostate and colorectal cancers. The company offers a range of diagnostic tests, including the PCA3 test for prostate cancer and the Previstage GCC colorectal cancer staging test.
What do analysts say about DGCRF stock?
Given the OTC Other listing and limited information available, formal analyst coverage of DGCRF is unlikely. Investment considerations should focus on the company's financial stability, the market potential of its diagnostic tests, and its ability to compete in the specialized medical diagnostics market. Key valuation metrics would include revenue growth, gross margin, and operating expenses.
What are the main risks for DGCRF?
Diagnocure, Inc. faces several key risks, including competition from larger diagnostic companies, regulatory changes affecting diagnostic testing, and technological advancements rendering existing tests obsolete. As an OTC-listed company, DGCRF is subject to greater scrutiny and potential volatility.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Diagnocure, Inc.
- OTC Other listing indicates higher risk and limited liquidity.